- Home
- GOF vs NVCR Comparison
GOF vs NVCR Comparison
Compare GOF & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOF | NVCR |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2006 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GOF | NVCR |
|---|---|---|
| Price | $8.45 | $13.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $26.86 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 01-01-0001 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $10.80 |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $8.40 | $9.82 |
| 52 Week High | $14.02 | $21.45 |
Technical Indicators
Market Signals| Indicator | GOF | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 35.54 | 35.32 |
| Support Level | $8.40 | $13.43 |
| Resistance Level | $10.74 | $14.29 |
| Average True Range (ATR) | 0.18 | 0.58 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 7.63 | 8.58 |
Price Performance
Historical ComparisonAbout GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The Fund's investment objective is to maximize total return through a combination of current income and capital appreciation. It has single operating segment. Its products are Mutual Funds, Wealth Management SMAS, Institutional SMAS, ETFS, UITS, UCITS, CIT, Closed-End Funds, Private Funds, Rydex Funds, and Variable Insurance funds.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.